Sitafloxacin

Sitafloxacin 구조식 이미지
카스 번호:
127254-12-0
상품명:
Sitafloxacin
동의어(영문):
spifloxacin;Sitfloxacfn;Sitafloxacfn;The west was;Sitafloxacin-d4;Sitafloxacin anhydrous;Sitafloxacin (DU-6859a);Sitafloxacin ABCDEFGHJKL;7-((S)-7-Amino-5-azaspiro[2.4]heptan-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4;7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylicaci
CBNumber:
CB8222468
분자식:
C19H18ClF2N3O3
포뮬러 무게:
409.81
MOL 파일:
127254-12-0.mol

Sitafloxacin 속성

끓는 점
629.2±55.0 °C(Predicted)
밀도
1.63±0.1 g/cm3(Predicted)
저장 조건
Store at -20°C
용해도
DMF: slightly soluble; DMSO: slightly soluble; Methanol: slightly soluble
물리적 상태
결정성 고체
산도 계수 (pKa)
6.39±0.50(Predicted)
CAS 데이터베이스
127254-12-0(CAS DataBase Reference)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 피부에 자극을 일으킴 피부부식성 또는 자극성물질 구분 2 경고 GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 눈에 심한 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2A 경고 GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 호흡 자극성을 일으킬 수 있음 특정 표적장기 독성 - 1회 노출;호흡기계 자극 구분 3 경고 GHS hazard pictograms
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P264 취급 후에는 손을 철저히 씻으시오.
P264 취급 후에는 손을 철저히 씻으시오.
P270 이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.
P271 옥외 또는 환기가 잘 되는 곳에서만 취급하시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P301+P312 삼켜서 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
P302+P352 피부에 묻으면 다량의 물로 씻으시오.
P304+P340 흡입하면 신선한 공기가 있는 곳으로 옮기고 호흡하기 쉬운 자세로 안정을 취하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P330 입을 씻어내시오.
P332+P313 피부 자극이 생기면 의학적인 조치· 조언을 구하시오.
P337+P313 눈에 대한 자극이 지속되면 의학적인 조치· 조언를 구하시오.
P362 오염된 의복을 벗고 세척 후에 재사용하기
P403+P233 용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.
P405 밀봉하여 저장하시오.
P501 ...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
2 0

Sitafloxacin C화학적 특성, 용도, 생산

개요

Sitafloxacin hydrate is the newest member (fourth generation) of the fluoroquinolone family of antibiotics that exhibits broad spectrum activity against many Gram-positive, Gramnegative, and anaerobic clinical isolates, including strains resistant to other fluoroquinolones. Since the launch of the first fluoroquinolone norfloxacin (patented in 1978), 20 other versions have made it to market with ciprofloxacin and levofloxacin experiencing the most prevalent usage. The mechanism of action involves inhibition of bacterial type II topoisomerases, both DNA gyrase and topoisomerase IV. By inhibiting these enzymes and preventing DNA supercoiling, cell division is disrupted leading to cell death. In Gram-negative bacteria, the primary target appears to be gyrase, whereas topoisomerase IV is involved in Gram-positive bacteria. Dual inhibition is attractive for widespread activity and avoidance of resistance as both encoding genes would have to acquire mutations.

용도

Antibacterial (DNA-gyrase inhibitor).

Pharmaceutical Applications

A group 4 quinolone formulated for oral or intravenous use. In-vitro activity is similar to or better than that of moxifloxacin. The antibacterial spectrum covers Gram-positive and Gram-negative bacteria including anaerobes. It has a chlorine atom at the C-8 position, and therefore has potential for phototoxicity. Early interest in this compound has not been maintained, but it is available in Japan.

부작용

As a class, the major adverse events for fluoroquinolones are cardiac arrhythmia (due to QT interval 622 Shridhar Hegde and Michelle Schmidt prolongation), major phototoxicity, CNS disturbances (seizures, dizziness, and headaches), and tendonitis. The GI side effects, common to most antimicrobials, include Clostridium difficile-associated diarrhea (CDAD) and alterations in glucose homeostasis. From the clinical safety profile of sitafloxacin (1,059 patients receiving either 50 mg b.i.d. or 100 mg b.i.d.), about a third of patients experienced an adverse event with the most common being diarrhea, liver enzyme elevations, and headaches; however, the risk of QT prolongation, hypoglycemia, and hepatotoxicity were all considered to be low. Phototoxicity appears to be the limiting toxicity, particularly in non-Asian patients.

Sitafloxacin 준비 용품 및 원자재

원자재

준비 용품


Sitafloxacin 공급 업체

글로벌( 136)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 - 03@
sales03@shyrchem.com CHINA 738 60
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 967 58
Shanghai Yingrui Biopharma Co.,Ltd
21-33585366
export01@shyrchem.com CHINA 1320 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 47465 58
career henan chemical co
+86-0371-86658258 15093356674;
factory@coreychem.com China 29826 58
Shaanxi Dideu Medichem Co. Ltd
18192627656
1012@dideu.com China 3911 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29831 58
AFINE CHEMICALS LIMITED
0571-85134551
info@afinechem.com CHINA 15377 58
Baoji Guokang Bio-Technology Co., Ltd.
0917-3909592 13892490616
gksales1@gk-bio.com China 9340 58
Baoji Guokang Healthchem co.,ltd
+8615604608665 15604608665
dominicguo@gk-bio.com CHINA 9427 58

Sitafloxacin 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved